drugset / Trial / NCT01407562
Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors
Phase 1
Terminated
34 enrolled
Rutgers, The State University of New Jersey
GlaxoSmithKline · collabNational Cancer Institute (NCI) · collabRutgers Cancer Institute of New Jersey · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, dose escalation study to determine the safety and tolerability and maximum tolerated dose of pazopanib combined with weekly paclitaxel and carboplatin in patients with advanced solid tumors.
Timeline
- Start
- 2010-09-17
- Primary completion
- 2016-03-29
- Completion
- 2016-03-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pazopanib | Small molecule | 400 unknown | — |
| Background | Carboplatin | Small molecule | 2 unknown | Intravenous |
| Background | Paclitaxel | Small molecule | 60 mg/m2 | Intravenous |